IN8bio, a clinical-stage biopharmaceutical company, has expanded its Phase 1 clinical trial for INB-100.
The Ohio State University is now a new clinical site for the trial. This expansion aims to accelerate enrollment and completion of the study.
INB-100 Clinical Trial
The INB-100 trial is evaluating a donor-derived gamma-delta T cell therapy for leukemia patients undergoing haploidentical stem cell transplantation. The trial seeks to reduce the risk of relapse and graft-versus-host disease.
Key Trial Information
| Trial Name | Therapy | Focus | Primary Investigator |
| INB-100 | Allogeneic gamma-delta T cells | Leukemia patients post-stem cell transplant | Dr. Joseph P. McGuirk |
The Ohio State University’s Role
The Ohio State University’s addition as a clinical site is expected to accelerate the trial. Dr. Sarah A. Wall, an investigator at The Ohio State University, will lead the trial at The James Comprehensive Cancer Center.
“This trial is an excellent opportunity to explore a strategy aimed at reducing the risk of graft-versus-host disease and the risk of relapse following haploidentical stem cell transplant,” said Dr. Wall.
IN8bio’s Perspective
William Ho, CEO of IN8bio, expressed excitement about the partnership. He highlighted the potential of gamma-delta T cells to improve patient outcomes.
“INB-100 continues to demonstrate the potential of gamma-delta T cells to improve outcomes and reduce relapse in patients following stem cell transplantation,” said Ho.
About IN8bio
IN8bio develops gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases. The company’s lead program, INB-100, focuses on acute myeloid leukemia.
This expansion marks a significant step in the development of new leukemia therapies. The collaboration between IN8bio and The Ohio State University aims to bring innovative treatments to patients faster.
More info: https://in8bio.com/
References
[1] IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
